huahaipharm(600521) 证券时报网·2025-03-07 18:58Group 1 - The core viewpoint of the article emphasizes the need for high-quality development in the pharmaceutical industry, with specific recommendations from Chen Baohua, President of Huahai Pharmaceutical, during the National People's Congress [1] - Chen Baohua proposed six suggestions related to the pharmaceutical industry, including the addition of "export exemptions" in the drug patent compensation system and regulations for segmented production of raw materials [1][2] - The suggestion to accelerate the inclusion of China's drug regulatory system in the World Health Organization's WLA list is highlighted, aiming to enhance international recognition and facilitate the global expansion of Chinese pharmaceutical companies [1] Group 2 - The article discusses the shortcomings in the development and production of high-value-added raw materials in China's pharmaceutical industry, emphasizing the need for regulations and guidelines for segmented production to ensure a stable supply chain [2] - Specific recommendations include allowing both domestic and foreign applicants to implement segmented production and clarifying the scope of contract manufacturing regulations for raw materials [2] - Chen Baohua also calls for improvements in the selection policy for reference preparations of domestic new drugs, addressing issues such as delays in the selection process and obstacles in the development of generic drugs [2] Group 3 - Huahai Pharmaceutical is identified as a major global manufacturer of cardiovascular and mental health medical products, with a unique vertical integration advantage in its industry chain [3] - The company's business has expanded to cover various categories, including innovative drugs, biopharmaceuticals, and cell therapy [3]